Exicure, Inc. (XCUR) stock
XCURNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.08+0.01 (+0.93%)
Close on Nov 17, 2026Market cap $7.07MP/E –Yield –
Exicure EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Exicure's EPS for the twelve months ending Jun 30, 2026 was -$1.31. For fiscal 2025 it was -$0.79. The highest annual figure on record is -$0.79 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$0.79 | – |
| FY2024 | Dec 31, 2024 | -$4.75 | – |
| FY2023 | Dec 31, 2023 | -$10.55 | – |
| FY2022 | Dec 31, 2022 | -$2.80 | – |
| FY2021 | Dec 31, 2021 | -$108.50 | – |
| FY2020 | Dec 31, 2020 | -$42.00 | – |
| FY2019 | Dec 31, 2019 | -$69.00 | – |
| FY2018 | Dec 31, 2018 | -$81.00 | – |
| FY2017 | Dec 31, 2017 | -$163.50 | – |
| FY2016 | Dec 31, 2016 | -$22405.50 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$0.18 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.29 | -159.2% |
| Q4 FY2025 | Dec 31, 2025 | -$0.45 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.39 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.41 | – |
| Q1 FY2025 | Mar 31, 2025 | $0.49 | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.75 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.57 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.35 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.48 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.86 | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.04 | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.40 | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.50 | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.20 | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.30 | – |
| Q1 FY2022 | Mar 31, 2022 | -$10.35 | – |
| Q4 FY2021 | Dec 31, 2021 | -$22.92 | – |
| Q3 FY2021 | Sep 30, 2021 | -$40.05 | – |
| Q2 FY2021 | Jun 30, 2021 | -$24.30 | – |
| Q1 FY2021 | Mar 31, 2021 | -$21.00 | -1500.0% |
| Q4 FY2020 | Dec 31, 2020 | -$22.50 | – |
| Q3 FY2020 | Sep 30, 2020 | -$15.00 | – |
| Q2 FY2020 | Jun 30, 2020 | -$7.50 | – |
| Q1 FY2020 | Mar 31, 2020 | $1.50 | – |
| Q4 FY2019 | Dec 31, 2019 | -$19.50 | – |
| Q3 FY2019 | Sep 30, 2019 | -$13.50 | – |
| Q2 FY2019 | Jun 30, 2019 | -$18.00 | – |
| Q1 FY2019 | Mar 31, 2019 | -$18.00 | – |
| Q4 FY2018 | Dec 31, 2018 | -$16.50 | – |
| Q3 FY2018 | Sep 30, 2018 | -$19.50 | – |
| Q2 FY2018 | Jun 30, 2018 | -$25.50 | – |
| Q1 FY2018 | Mar 31, 2018 | -$21.00 | – |
| Q4 FY2017 | Dec 31, 2017 | -$13.50 | – |
| Q2 FY2017 | Aug 31, 2017 | -$1.50 | – |
| Q4 FY2016 | Dec 31, 2016 | -$6764.99 | – |
| Q3 FY2016 | Sep 30, 2016 | -$5413.50 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?